Social Media

Nearly 40% of patients with AL amyloidosis wait more than a year for a diagnosis.By the time many are referred, the heart is already silently, irreversibly damaged…

🚨 New Cardio Town Hall: Expert Perspectives on Contemporary ATTR-CM Clinical ResearchThe treatment landscape for transthyretin amyloidosis with cardiomyopathy (ATTR…

Amyloidosis is a rare, progressive disease, and delays in treatment can lead to permanent heart and nerve damage. Morie A. Gertz, MD, explains why timely access to…

From the NI006-101 trial, long-term follow-up of cliramitug treatment in patients with transthyretin amyloidosis cardiomyopathy showed favorable safety and…

If you’re living with hereditary hATTR neuropathy (or know somebody else who is), we’ve launched a survey on our website to help healthcare professionals better…

Living with hereditary transthyretin amyloid cardiomyopathy can be overwhelming. See how to care for your mental health.

Hereditary transthyretin amyloid cardiomyopathy is undertreated in Black people. What does this doctor want you to know?

Hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) goes beyond meds. Learn how diet & movement changes may help.

New caregiver guide 👉 Caregiving Through Amyloidosis (ATTR): A Guide for FamiliesIf you are coordinating care, tracking symptoms, and seeking clear answers, this is…

Once staging is complete, treatment planning must be individualized based on disease severity, subtype (wild-type vs. hereditary), and comorbid conditions. This…